It looks like your browser is not up to date.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Enzon Pharmaceuticals Inc (ENZN) USD (CDI)

Sell:$0.53 Buy:$0.53 Change: $0.0256 (4.61%)
Market closed |  Prices as at close on 14 May 2021 | Switch to live prices |
Sell:$0.53
Buy:$0.53
Change: $0.0256 (4.61%)
Deal now Deal for just £11.95 per trade in a Fund and Share Account
Market closed |  Prices as at close on 14 May 2021 | Switch to live prices |
Sell:$0.53
Buy:$0.53
Change: $0.0256 (4.61%)
Market closed |  Prices as at close on 14 May 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Enzon Pharmaceuticals, Inc. receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products: PegIntron, Sylatron, Macugen and CIMZIA. The Company has no clinical operations and limited corporate operations. PegIntron is used both as a monotherapy and in combination with REBETOL (ribavirin) capsules for the treatment of chronic hepatitis C. Macugen is used for the treatment of neovascular (wet) age-related macular degeneration. Sylatron is used for the treatment of melanoma. CIMZIA is used for the treatment of moderate to severe rheumatoid arthritis and Crohn's disease. CIMZIA is a biologic medicine that counteracts tumor necrosis factor (or TNF), which promotes inflammation of the joints in rheumatoid arthritis.

Contact details

Address:
20 Commerce Drive, Suite 135
CRANFORD
07016
United States
Telephone:
+1 (732) 9804500
Website:
enzon.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ENZN
ISIN:
US2939041081
Market cap:
$43.04 million
Shares in issue:
74.21 million
Sector:
Biotechnology
Exchange:
Off Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Randolph Read
    Independent Chairman of the Board
  • Richard Feinstein
    Chief Executive Officer, Chief Financial Officer, Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.